Neurodegenerative Disease Research
Wake Forest University Health Sciences is involved in clinical research focused on amnestic mild cognitive impairment and early-stage Alzheimer’s disease, with attention to conditions marked by early cognitive decline and biomarker-defined disease activity.
- Alzheimer’s disease
- Amnestic mild cognitive impairment
- Early cognitive decline
The sponsor’s research activity in this area centers on identifying therapeutic strategies relevant to the transition from mild impairment to more advanced neurodegenerative disease.
Senolytic and Cellular Senescence Studies
The sponsor funds research examining senolytic therapy and its relationship to cellular senescence, reflecting interest in biological pathways that may influence neurodegeneration.
- Senolytic therapy
- Cellular senescence
- Biomarker-based intervention research
Investigations include assessment of blood-based markers associated with senescence and their relevance to cognitive disorders.
Biomarker-Guided Neurology
Clinical interest extends to cerebrospinal fluid biomarkers, particularly tau measures used to characterize disease activity in participants with early Alzheimer’s-related syndromes.
- Cerebrospinal fluid tau
- Neurological biomarker profiling
- Disease characterization
This area supports research linking molecular markers with clinical features of cognitive impairment.
Translational Cognitive Disorder Research
The sponsor’s trial portfolio includes work at the interface of clinical neuroscience and therapeutic development for memory disorders, with emphasis on interventions that may alter disease-related biology in adults with measurable cognitive symptoms.
- Clinical neuroscience
- Memory disorders
- Therapeutic development
Research activity is concentrated in a single active study site in the United States, reflecting a focused clinical interest in neurocognitive disease management.
